Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 210M 252M 225M 190M 358M 23.9B 360M 2.51B 983M 12.43B 946M 925M 39.88B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 230M 276M 247M 208M 392M 26.21B 395M 2.75B 1.08B 13.63B 1.04B 1.01B 43.75B EV / Sales 2026 *
2.43x
EV / Sales 2027 * 1.93x
Free-Float
84.85%
Yield 2026 *
-
Yield 2027 * -
1 day+1.39%
1 week-4.09%
Current month-9.16%
1 month-9.51%
3 months-7.49%
6 months-20.36%
Current year+11.75%
1 week 13.42
Extreme 13.42
14.62
1 month 13.42
Extreme 13.42
16.28
Current year 11.7
Extreme 11.7
18.84
1 year 9.57
Extreme 9.57
18.84
3 years 7.21
Extreme 7.21
18.84
5 years 5
Extreme 5
20.3
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 2026-07-14
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
1/22/24 Buy 30,228 0.2396%
7/6/23 Buy 2,000 0.0016%
1/11/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-4.09%+46.97%+40.94% 252M
+3.47%+1.41%+48.40%+95.49% 1,040B
+1.39%-2.61%+31.88%+59.78% 599B
+3.29%+4.14%+23.34%+91.94% 485B
+2.34%+1.35%+70.86%+38.97% 350B
+2.88%+2.69%+29.18%+46.62% 345B
+2.51%+1.67%+17.28%+39.93% 272B
+3.34%+0.62%-3.78%+11.70% 244B
+3.30%+2.91%+44.66%+48.17% 223B
+2.37%+2.85%+27.48%+90.71% 183B
Average +2.61%+1.12%+33.63%+56.43% 374.3B
Weighted average by Cap. +2.80%+2.31%+35.92%+66.94%

Financials

2026 *2027 *
Net sales 94.7M 114M 102M 85.86M 162M 10.8B 163M 1.13B 444M 5.61B 427M 418M 18.02B 116M 139M 124M 105M 197M 13.17B 199M 1.38B 542M 6.85B 521M 510M 21.98B
Net income - -
Net Debt 20.3M 24.38M 21.78M 18.4M 34.64M 2.31B 34.91M 243M 95.2M 1.2B 91.56M 89.55M 3.86B 13.4M 16.09M 14.38M 12.15M 22.86M 1.53B 23.04M 161M 62.84M 794M 60.44M 59.11M 2.55B
Projected Income Statement - Annual - Santhera Pharmaceuticals Holding AG
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
26-10-14 CHF 14.08 +2.77% 54,876
26-10-13 CHF 13.70 -6.04% 91,162
26-10-12 CHF 14.58 +2.10% 27,118
26-10-09 CHF 14.28 +0.99% 52,127
26-10-08 CHF 14.14 -3.68% 94,070
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Santhera Pharmaceuticals Holding AG
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.70CHF
Average target price
27.50CHF
Spread / Average Target
+100.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Santhera Pharmaceuticals Holding AG
  1. Stock Market
  2. Stocks
  3. SANN Stock